



The IU Health Precision Genomics program is changing cancer care by partnering with you.

- Your patients remain your patients, and together you will decide which recommendations to pursue and when
- Your patients can remain close to home with our convenient locations across central Indiana
- •You and your patients get access to the most leading-edge science in genomic testing
- You and your patients get access to highly specialized experts where science meets the art of interpretation – this includes multidisciplinary clinical conference review, personalized recommendations and education
- You and your patient can receive assistance with pursuing approval for genomic-directed therapy recommendations, if needed

What can you expect from the recommendation?

Depending on the genomic analysis, past history and clinical conference recommendations, there are several options that may be recommended for your patients, including:

- Pharmacological therapies approved by the FDA for other indications
- Clinical trials of targeted therapies
- ■Phase I or Phase II clinical trials at IU Health or other centers across the Midwest



OUTCOMES OF OUR PROGRAM

20% RECEIVED GENOMIC-DIRECTED RECOMMENDATION AND PROCEEDED TO THERAPY

83% RECEIVED GENOMIC-DIRECTED RECOMMENDATIONPatients will receive a new treatment recommendation, whether that is a new drug or clinical trial participation or both.

17% DID NOT RECEIVE GENOMIC-DIRECTED RECOMMENDATIONS Results of genomic testing indicated that our program does not have any additional genomic-based treatment options to recommend.

Precision Genomics at IU Health: Step by step



- **1.** Review and refer. Talk with your patient about the Precision Genomics program and how it functions. If you and your patient would like to participate in this program, refer your patient to the nearest IU Health Precision Genomics location.
- **2. Initial patient consultation and testing.** If your patient is eligible and accepted by the program, they will meet with a precision genomics team at an IU Health location.


During this appointment, they will:

- Learn more about the program and be able to ask questions
- Be examined by one of our medical oncologists
- Have blood drawn
- Have a biopsy
- **3. Genomic testing.** Patients in our program will receive comprehensive testing of the cancer and may also receive germline DNA testing. This allows us to scan everything and have the most comprehensive view of the attributes of your patient's cancer.
- **4. Clinical Conference evaluation.** This is where science meets the art of interpretation. The IU Health Precision Genomics Clinical Conference is comprised of more than 20 multidisciplinary IU Health and IU School of Medicine faculty and staff, including oncologists, genomics scientists, pathologists, pharmacists, nurses and clinical trial specialists. This team will review the results of the genomic testing and will debate and discuss the best genomic-directed treatment options available to your patient.
- **5. Patient recommendation consultation.** Once the recommendations have been made by the clinical conference, your patient will return to the nearby Precision Genomics program for a second consultation to review the findings and recommendations. At this time, we are able to answer any specific questions your patient may have about the recommendations. Your patient should expect to attend this recommendation consultation about 6 8 weeks after their tissue has been submitted for testing.
- **6. Information sharing.** You will receive the genomic report, clinical notes, and our recommendation electronically or via fax, so you are always fully informed to speak with your patient.
- **7. Path forward.** Equipped with new, detailed information about your patient's tumor genetics, you and your patient will decide which recommendations to pursue and when.

Our program has been able to achieve results greater than many programs across the United States. We are dedicated to continue to increase the number of patients that are able to proceed to genomic-directed therapy.

The top reasons patients did not go on genomic-directed therapy were:

- Declining performance status of the patient
- Clinical trial availability/lack of availability
- Patient deciding they may pursue genomic-directed therapy in the future



Which patients are eligible for this program?

Patients with a solid tumor that has metastasized may be referred by their oncologist to the IU Health Precision Genomics program.

How soon should I refer my patients to the Precision Genomics program?

Patients can be referred as soon as they present with metastatic disease.

Is this program covered by insurance? Will my patient receive a bill?

Your patient's insurance may cover part or all of the program. In addition there is a patient assistance program for the genomic testing. While many patients receive generous assistance, the program is not free. Our team is happy to work with your patient on any financial questions, even in advance of entering the program.

For more information on the Precision Genomics program at IU Health, visit iuhealth.org/precision-genomics.

To refer a patient, contact us at a location near you.

Indianapolis

IU Health Simon Cancer Center: 317.948.9510

Muncie

IU Health Ball Memorial Cancer Center: 765.808.7982

Lafayette

IU Health Arnett Cancer Center: 765.838.6885

Bloomington

IU Health Bloomington Cancer Center: 812.676.4444

